NCT02751541 is a NA clinical trial of Sunscreen Sport Spray (BAY987519) in Sunscreening Agents, sponsored by Bayer.

Who is sponsoring NCT02751541?

NCT02751541 is sponsored by Bayer.

What drugs are being tested in NCT02751541?

Interventions in NCT02751541: Sunscreen Sport Spray (BAY987519), Untreated Skin.

What condition does NCT02751541 study?

NCT02751541 studies Sunscreening Agents.

Is NCT02751541 still recruiting?

NCT02751541 is currently completed. Last updated 13 December 2018.

Last reviewed 2018-12-13 · How we verify

NCT02751541

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Phototoxicity Test

Completed NA Last updated 13 December 2018

What this trial tests

NA trial testing Sunscreen Sport Spray (BAY987519) in Sunscreening Agents in 35 participants. Completed in 6 May 2016.

Timeline

2 May 2016

Primary endpoint
6 May 2016

6 May 2016

Quick facts

Lead sponsor	Bayer
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	2 May 2016
Primary completion	6 May 2016
Estimated completion	6 May 2016
Sites	1 location across United States

Drugs / interventions tested

Sunscreen Sport Spray (BAY987519) — full drug profile →
Untreated Skin

Conditions studied

Sunscreening Agents — all drugs for Sunscreening Agents →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 60, any sex, with Sunscreening Agents. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the phototoxic potential of a topically applied article in human subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02751541 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 13 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02751541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing